人乳頭瘤病毒感染是導(dǎo)致女性患宮頸癌的罪魁禍?zhǔn)?。美?guó)一項(xiàng)最新研究成果顯示，男性感染人乳頭瘤病毒的情況也比較普遍,。
人乳頭瘤病毒屬于乳多空病毒科的乳頭瘤病毒屬,，能引起人類(lèi)皮膚和黏膜的多種良性乳頭狀瘤或疣，某些型別感染還具有潛在的致癌性,。
為了解男性感染人乳頭瘤病毒的幾率,，位于美國(guó)佛羅里達(dá)州的莫菲特·李癌癥中心的研究人員對(duì)1100名18歲至70歲的男性為研究對(duì)象，他們來(lái)自美國(guó),、巴西和墨西哥等國(guó)。結(jié)果發(fā)現(xiàn),，男性感染人乳頭瘤病毒的幾率高達(dá)50％,，與女性感染率十分接近。此外,，每年約有6％的男性會(huì)新感染人乳頭瘤病毒16型,，該型病毒是引發(fā)女性宮頸癌的最常見(jiàn)病毒，它可以導(dǎo)致男性患其他類(lèi)型癌癥,。
領(lǐng)導(dǎo)研究的安娜·朱利亞諾說(shuō),，研究表明，男性感染人乳頭瘤病毒的生理機(jī)制與女性類(lèi)似,；所不同的是,，部分女性可通過(guò)機(jī)體自身免疫系統(tǒng)將感染病毒清除，但男性不具備這種能力,。相關(guān)研究成果已發(fā)表在新一期《柳葉刀》醫(yī)學(xué)雜志上,。
目前，美國(guó)等西方國(guó)家的女性已開(kāi)始接種能預(yù)防人乳頭瘤病毒感染的疫苗,。專(zhuān)家建議,，由于男性感染該病毒幾率也較高，應(yīng)接種此疫苗,。（生物谷Bioon.com）
生物谷推薦原文出處：
The Lancet 2011 doi:10.1016/S0140-6736(10)62342-2
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study
Original TextProf Anna R Giuliano PhD a , Ji-Hyun Lee DrPH a, William Fulp MS a, Prof Luisa L Villa PhD b, Prof Eduardo Lazcano PhD c, Mary R Papenfuss MS a, Martha Abrahamsen MPH a, Jorge Salmeron MD c, Gabriella M Anic MSPH a, Dana E Rollison PhD a, Danelle Smith MS a
Summary
Background
Human papillomaviruses (HPVs) cause genital warts and cancers in men. The natural history of HPV infection in men is largely unknown, and that information is needed to inform prevention strategies. The goal in this study was to estimate incidence and clearance of type-specific genital HPV infection in men, and to assess the associated factors.
Methods
Men (aged 18—70 years), residing in Brazil, Mexico, and the USA, who were HIV negative and reported no history of cancer were recruited from the general population, universities, and organised health-care systems. They were assessed every 6 months for a median follow-up of 27·5 months (18·0—31·2). Specimens from the coronal sulcus, glans penis, shaft, and scrotum were obtained for the assessment of the status of HPV genotypes.
Findings
In 1159 men, the incidence of a new genital HPV infection was 38·4 per 1000 person months (95% CI 34·3—43·0). Oncogenic HPV infection was significantly associated with having a high number of lifetime female sexual partners (hazard ratio 2·40, 1·38—4·18, for at least 50 partners vs not more than one partner), and number of male anal-sexual partners (2·57, 1·46—4·49, for at least three male partners vs no recent partners). Median duration of HPV infection was 7·52 months (6·80—8·61) for any HPV and 12·19 months (7·16—18·17) for HPV 16. Clearance of oncogenic HPV infection decreased in men with a high number of lifetime female partners (0·49, 0·31—0·76, for at least 50 female partners vs not more than one partner), and in men in Brazil (0·71, 0·56—0·91) and Mexico (0·73, 0·57—0·94) compared with the USA. Clearance of oncogenic HPV was more rapid with increasing age (1·02, 1·01—1·03).
Interpretation
The data from this study are useful for the development of realistic cost-effectiveness models for male HPV vaccination internationally.
Funding
National Cancer Institute.
